Using AI to improve MRI screening for breast cancer in high-risk women
Peking University People's Hospital Breast Center
This study is testing if using AI can make MRI screenings for breast cancer quicker and easier for high-risk women while still providing accurate results.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Sex | Female |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Beijing, Bei Jing and 1 other locations) |
| Trial ID | NCT04996615 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of Convolutional Neural Networks to analyze contrast-enhancing lesions in multiparametric breast MRI for high-risk women. It aims to develop an abbreviated MRI protocol that reduces examination time and avoids the need for enhanced imaging while maintaining diagnostic accuracy. The study focuses on high-risk Chinese women and evaluates the effectiveness of this approach through a follow-up database to confirm diagnosis outcomes. No interventions are applied, as the study is observational in nature.
Who should consider this trial
Good fit: Ideal candidates are high-risk women who are undergoing full sequence breast MRI examinations.
Not a fit: Patients who have previously received treatments like radiotherapy or chemotherapy for breast cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more efficient and accurate breast cancer screening for high-risk women.
How similar studies have performed: While the use of AI in medical imaging is gaining traction, this specific approach focusing on abbreviated MRI protocols in high-risk populations is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing full sequence BMRI examination * Written informed consent and complete the clinical data questionnaire * Through the follow-up database, at least 6 months of follow-up results can be obtained to determine whether the diagnosis result is negative/benign/malignant; for patients who need pathological biopsy, the pathological biopsy results shall prevail to determine the lesion benign/malignant. Exclusion Criteria: * The breast had received radiotherapy, chemotherapy, biology and other treatments before BMRI. * Signs or symptoms of breast disease * There are contraindications for breast-enhanced MRI examinations such as allergy to contrast agents. * Patients during lactation or pregnancy
Where this trial is running
Beijing, Bei Jing and 1 other locations
- Peking university people's hospital — Beijing, Bei Jing, China (Recruiting)
- Peking University People's Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: shu wang, doctor
- Email: shuwang@pkuph.edu.cn
- Phone: 86+010-88324010
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.